

## Hematological Indices for Mice Bearing Ehrlich Tumor When Treated by Liposomes Encapsulated Hemoglobin and Irradiation

M.I. El Gohary, S.A. Ali<sup>#</sup>, N.A. Deiab<sup>\*\*</sup>, M.M. Ismail and M.H. Gaber<sup>\*</sup>

*Physics Department, Faculty of Science (Boys), Al-Azhar University, Nasr City; \*Biophysics Department, Faculty of Science, Cairo University and \*\*Medical Physics Department, National Cancer Institute "NCI", Cairo University, Cairo Egypt.*

**T**UMOR vasculature frequently fails to supply sufficient levels of oxygen to tumor tissue resulting in radioresistant tumor. To improve therapeutic outcome radiotherapy (RT) may be combined with liposomes encapsulated bovine hemoglobin (LEBH) as an artificial oxygen carrier. Hematological parameters and lipid peroxidation (LPx) can be indicators for tumor prediction and treatment. The aim of the present work is to investigate and compare the effects of combination between radiotherapy and liposome encapsulated bovine hemoglobin as artificial oxygen carriers through hematological parameters and lipid peroxidation (LPx). This study was done through five groups of Male Swiss albino mice's bearing Ehrlich Ascites Carcinoma (EAC).

Blood samples were collected from mices of different groups into a tube containing heparin (heparinized tube).

Erythrogram, (LEBH+RT) group shows promising values in most measurements comparable to (RT) group and control group. Meanwhile, (Control) group shows low erythrogram values if compared to (Normal) group, but (LEH) shows the highest erythrogram values when compared to all investigated groups.

The hematological studies suggest that LEBH may have the potential of synergistic action with radiotherapy based on the tumor oxygenation effect of LEBH.

**Keywords:** Liposomes, Hypoxic tumor, Radiotherapy, Ehrlich ascites carcinoma (EAC), Erythrogram, Lipid peroxidation (LPx).

Hemoglobin (Hb) has been encapsulated using lipid bilayer membranes to form Hb vesicles (HbV), in order to produce a blood like hemoglobin-based Oxygen carriers (HBOC) where the oxygen carrying Hb is not dissolved in plasma<sup>(1, 2)</sup>.

---

<sup>#</sup> For Correspondence e-mail: saidtaha@aucegypt.edu

Artificial oxygen carriers lack blood types, are free of potential infectious pathogens, and can be stored much longer than red blood cells (RBCs)<sup>(3)</sup>.

Hemoglobin (Hb)-based oxygen carriers are classified into acellular chemically modified Hbs and encapsulated Hbs<sup>(4, 5)</sup>. The cellular structure of HbV has characteristics that resemble those of RBCs. It has lipid bilayer membranes that prevent the direct contact of hemoglobin with blood components and the endothelial lining, thus shielding the side effects of molecular hemoglobin<sup>(6, 7)</sup>. HbV particles are eventually captured by the phagocytes in the reticuloendothelial system and are metabolized through existing physiological pathways<sup>(8-10)</sup>.

Mounting evidence has disclosed that hypoxia protects tumor cells against cytotoxic actions of radiation therapy or chemotherapeutic agents<sup>(11, 12)</sup>. As this is the mechanism of therapeutic resistance of the tumor, there have been various attempts to modify tumor hypoxia to enhance the sensitivity of these therapies, including hyperbaric oxygen therapy (HBO) (3), oxygen (O<sub>2</sub>)-mimetic chemical radiosensitizer<sup>(13,14)</sup>, perfluorochemicals (PFCs)<sup>(15,16)</sup>, modified hemoglobin<sup>(17)</sup>, and hypoxic cytotoxin and mild hyperthermia<sup>(18)</sup>. These various methods and/or medicines as hypoxic cell modifiers have been tested in preclinical experiments and clinical trials. A recent meta-analysis of these clinical trials<sup>(19)</sup> suggests that HBO has been most effective, showing the highest odds ratio, as a hypoxic modifier.

Hematological profile is measured all over the world to estimate general health, because it is a reliable indicator and is a simple, fast and cost-effective test.<sup>(20)</sup> In addition, the hematological profile is considered to be one of the factors affecting pregnancy and its outcome<sup>(21,22)</sup>.

Hematological parameters are a very useful tool in alarming by several tumors. The white blood cell count (total and differentials) and packed cell volume predict disease severity and mortality risk<sup>(23-26)</sup>. For example, elevated WBCs counts predict a worse prognosis in patients with cancer or coronary artery disease and anemia predicts increased risk of death of cancer patients with heart failure<sup>(27-30)</sup>.

Many conditions will result in increase or decrease in the cell populations. Some of these conditions may require treatment, while others will resolve on their own. Some diseases, such as cancer (and chemotherapy treatment), can affect bone marrow production of cells, increasing the production of one cell at the expense of others or decreasing overall cell production. Some medications can decrease WBCs counts while some vitamin and mineral deficiencies can cause anemia. The CBC test may be ordered on a regular basis to monitor these conditions and drug treatments.

Cancer is considered as a multifactor disease, where oxidative stress may be involved in both initiation and promotion of multi-step carcinogenesis. Reactive

oxygen species (ROS) can accelerate DNA damage, stimulate pro-carcinogenesis, initiate lipid peroxidation (LPx), inactivate antioxidant enzyme systems and thus can modulate the expression of genes related to tumor promotion<sup>(31,32)</sup>.

Excessive production of free radicals cause macromolecular damage and can induce lipid peroxidation *in vivo*<sup>(33)</sup>. Malondialdehyde (MDA) the end product of lipid peroxidation (LPx), are seen to be higher in cancer tissues than in non-diseased organ<sup>(34)</sup>.

Therefore, this work examines liposomes encapsulating bovine hemoglobin as potential oxygen carriers to increase the efficiency of radiation effect on tumors where oxygen dept in tumor area is considered one of the primary factors of tumor resistance to radiation effect. To assess the feasibility of using LEBH as oxygen transporters, hematological parameters and lipid peroxidation were examined on Mice Bearing Ehrlich Ascites Carcinoma.

### Material and Methods

#### *Characteristics of liposome encapsulated hemoglobin*

The characteristics of liposomes encapsulated bovine hemoglobin (LEBH) are very important to be determined before *in vivo* study, thus the mean particle diameter, phase transition temperature, hemoglobin concentration, encapsulation efficiency, pH and relative osmolarity are carried out (work is not presented here).

#### *Cell culture and tumor model*

Ehrlich asites tumor was chosen as a rapidly growing experimental tumor model<sup>(35)</sup> where various experimental designs for anticancer agents can be applied. Ehrlich ascites carcinomas cells ( $1 \times 10^6$  cells), obtained from National Cancer Institute "NCI" – Cairo University were intraperitoneally injected into female Swiss albino mice as a donor. Ascites fluid was collected from the donor mice on the 7<sup>th</sup> day after injection. The Ehrlich cells were washed twice and then re-suspended in 0.05 saline ( $5 \times 10^6$  viable cells). Male Swiss albino mices (obtained from animal house at National Cancer Institute, Cairo University) were then injected subcutaneously in their right flanks where the tumors were developed in a single and solid form. Apalpable solid tumor mass (about  $\geq 100$  mm<sup>3</sup>) was developed within 12 days<sup>(36, 37)</sup>. Tumor growth was monitored post-inoculation until the desired volume was reached.

#### *Animal care*

*In vivo* studies were done on a total of 50 male Swiss albino mice 8 weeks old, weighing 22–25 g, purchased from animal house at National Cancer Institute, Cairo University. Each group (Ten animals) were housed in plastic cages in a well-ventilated room ( $26 \pm 2$  °C) with a relative humidity of ( $40 \pm 2$  %), 12 h light/12 h dark cycle and free access to feed and water. All animal procedures and care were performed using guidelines for the Care and Use of Laboratory Animals<sup>(38)</sup> and approved by the Animal Ethics Committee at Cairo University.

### *Classification of animals*

*In vivo* studies are done on a total of 50 male Swiss albino mice. The experimental animals are divided randomly into 5 equal groups of ten mice each as follows: Group (1): The Normal (mice neither have tumor nor receive treatment) group. Group (2): The control (untreated) group. Group (3): LEBH injected group (mice injected with LEBH only). Group (4): Radiotherapy (RT) group (mice receive radiation dose only). Group (5): Combined treatment of LEBH and RT (mice receive radiation dose after administration with LEBH). Animals were anesthetized with thiopental sodium (40 mg/kg) was administered intraperitoneally (IP) to each mouse, and the dose of LEBH administered to each mouse in group 3 and 5 was equivalent to 10 mg/kg which were suspended in saline and sonicated for 10 min before injection to get a homogenous suspension then directly injected intravenous (IV) into the tumor interstitial coordinates using insulin syringe. Two groups (4 and 5) of mice were specified to receive radiation dose (20-Gy, single shot). Group (4) were restrained in acrylic holders and received local irradiation to the tumors at a dose rate of 1.2 Gy/min using 4MV X-rays by linear accelerator (Clinac 600C, Varian Medical Systems, Palo Alto, CA, USA) under room air. Then, group (5) received 10 ml/kg of LEBH 30 min before the same radiation dose as group (4) at the same circumstances<sup>(39)</sup>.

### *Blood sampling*

A blood sample is collected from mice of different groups (after 21 days of starting treatment) using a dry, sterile disposable syringe and needle. The blood is dispensed into heparinized tubes. The specimens were labeled with identification number.

### *Laboratory analysis*

Blood count was performed using a SK9000 Hematology auto Analyzer (Labomed, Inc, USA). Standardization, calibration of the instrument, and processing of the samples were done according to the manufacturer's instructions.

### *Procedures*

Each blood sample is mixed well and then approximately 20  $\mu$ L is aspirate by allowing the analyzer's sampling probe into the blood sample and depressing the start button. Results of the analysis are displayed after about 30 seconds, after which the analyzer generated a paper copy of the results on thermal printing paper.

### *Lipid peroxidation (LPx) estimation*

Lipid peroxidation (LPx) in blood is observed by the formation of malonaldehyde (MDA) as one of the main products of lipid peroxidation using Thiobarbituric acid (TBA) and measured as described by Yoshioka *et al*<sup>(40)</sup>.

### *Statistical analysis*

The results are expressed as mean  $\pm$  SD. Differences between groups are assessed by t-test analysis of variance. The changes are considered statistically significant if  $p < 0.05$ .

## Results and Discussion

### Hematological parameters

In Fig. 1, group (LEBH+RT) shows high value comparable to (RT) and (Control) groups although (LEBH+RT) group receive the same radiation dose as (RT) group, also (LEBH) group achieved the highest value of the different groups.




Fig. 1. RBCs concentration for investigated groups, \*P<0.05 (Normal vs. other groups).


In the erythrogram (Table 1), (LEBH+RT) group show high values in most measurements comparable to (RT) group. Also, (Control) group show low erythrogram values comparable to (Normal) group, but (LEBH) show the highest erythrogram values comparable to all investigated groups.

TABLE. 1. Erythrogram for investigated groups (mean  $\pm$  SD).

Group	HGB g/dl	HCT %	MCV fl	MCH pg	MCHC g/dl	RDW-CV %
NORMAL	9.6 $\pm$ 2.77	29.8 $\pm$ 2.54	42.8 $\pm$ 5.23	13.8 $\pm$ 2.51	32.3 $\pm$ 4.72	8 $\pm$ 0.76
CONTROL	9.2 $\pm$ 3.04	24 $\pm$ 3.98	60 $\pm$ 6.34	22.9 $\pm$ 3.78	38.3 $\pm$ 5.76	19.7 $\pm$ 3.41
LEH	12.3 $\pm$ 2.3	28.3 $\pm$ 3.5	52.1 $\pm$ 4.62	22.6 $\pm$ 3.04	43.4 $\pm$ 5.16	16.6 $\pm$ 4.05
RT	5.4 $\pm$ 0.9	15.4 $\pm$ 2.16	53.45 $\pm$ 4.09	16.8 $\pm$ 2.50	31.75 $\pm$ 3.78	17.9 $\pm$ 3.51
LEH+ RT	8.3 $\pm$ 1.1	26.3 $\pm$ 2.76	60.9 $\pm$ 3.12	19.2 $\pm$ 2.38	31.5 $\pm$ 2.83	20 $\pm$ 3.07

HGB: the total amount of hemoglobin in the blood; HCT: the fraction of the blood made up of RBCs; MCV: mean corpuscular volume; MCH: mean corpuscular hemoglobin; MCHC: mean corpuscular hemoglobin concentration; RDW-CV: red blood cell distribution width coefficient of variation.

In Fig. 2, there is high significant increase in WBCs value for (Control) and (LEH) groups which reach to about seven folds than the normal group. But (LEBH+RT) group showed the nearest value from the (Normal) group and lower values than (RT) group.



**Fig. 2. WBCs concentration for investigated groups, \*P<0.05 (Normal vs. other groups).**

In the leukogram (Table 2), there was a significant increase in values for WBCs differential cells in control and LEBH Groups. But (LEBH+RT) group showed also the nearest values from the (Normal) group and lower values than (RT) group.

**TABLE. 2. Leukogram for investigated groups (mean ± SD).**


Group	LYM# x 10 <sup>3</sup> /UL	MID# x 10 <sup>3</sup> /UL	GRAN# x 10 <sup>3</sup> UL	LYM%	MID%	GRAN%
NORMAL	6.4±1.77	1±0.12	1.9±0.31	68.7±4.9	10.5±3.15	20.8±3.95
CONTROL	28.1±3.35	20.4±2.01	17±3.15	42.8±5.87	31.1±2.66	26.1±2.0
LEH	23±2.25	18.6±3.72	20±2.7	37.4±3.5	30.2±2.99	32.4±3.51
RT	8.6±1.80	5.9±0.86	4.7±1.75	44.6±5.1	30.5±3.12	24.9±1.78
LEH+ RT	5.8±1.69	1.9±0.2	2.4±0.5	57.2±3.88	18.7±2.70	24.1±3.42

LYM: lymphocyte absolute count; MID: mid-range absolute count (includes monocytes, eosinophils and basophils); GRAN: Granulocyte absolute count.

#### *Malondialdehyde (MDA) concentration*

The lipid proxidation resulted in different investigated groups was assessed through measurement of MDA concentrations in blood samples of different group (Fig. 3).

As shown in Fig. 3, the high value of MDA concentration was for (Control) group followed by (RT) group. But (LEBH+RT) showed the lower value for different investigated groups including also (Normal) group.



**Fig. 3. MDA concentration for investigated groups. \*P<0.05 (Normal vs. other groups).**

#### Discussion

Hematopoietic stem cells are highly sensitive to ionizing radiation<sup>(41)</sup>. Hematopoietic recovery depends on the percentage of residual hematopoietic stem cells. As shown in erythrogram parameters, there was a considerable decrease in the hematological constituents in RT group in agreement with Benkovic *et al*<sup>(42)</sup>. The decrease in the values of erythrogram parameters following radiation exposure may be due to direct destruction of mature circulating cells, or leakage through capillary walls and reduced cell production<sup>(43)</sup>.

Although (LEBH+RT) group receive the same radiation dose as (RT) group, but (RT) group showed lower erythrogram values than (LEBH+RT) group, this support that LEBH enhances radiation therapy and improves tumor hypoxia<sup>(39)</sup>.

In leukogram (Table 2), the high values of leukocytes for Control and LEBH groups are an indication for the consequence of tumor growth<sup>(44)</sup>. In otherwise, obtained results of (LEBH+RT) group confirm that LEBH played an important role in healing tumor and improves radiation effect more than radiation effect alone<sup>(39)</sup>.

Lipid peroxidation has been suggested as one of the molecular mechanisms involved in radiation induced damage<sup>(45)</sup>. In the present study, the increased level of MDA for control and RT groups an index of lipid peroxidation may be due to the free radicals attack on cell membrane phospholipids and circulating lipids<sup>(46)</sup>.

Radiation is the main source of Reactive Oxygen Species (ROS) which lead to lipid peroxidation and elevation of MDA level<sup>(47)</sup>, that appears clearly in (RT) group otherwise (LEBH+RT) group although they receive the same radiation dose as (RT) group.

In control group, the highest MDA value and extreme oxidative damage is as a result of tumor growth<sup>(48)</sup>. Also, the activation process of leukocytes is accompanied by the intensive production of reactive oxygen species<sup>(49)</sup>.

It was observed that tumor cells produced more peroxides when they proliferate actively after inoculation of tumor<sup>(50)</sup>. This rise in peroxides indicates the occurrence of intensification of oxygen free radical production<sup>(51)</sup>.

### Conclusion

Liposome-encapsulated bovine hemoglobin is effective for tumor oxygenation and so enhancing radiation therapy not only against tumor growth in mice (data not shown in present work) but also in hematological parameters. The results suggests LEBH have a radical scavenging effect *in vivo* by encountering free radicals after tumor inoculation by inhibiting of membrane lipid peroxidation (LPx). Finally, our Findings clarify that LEBH may have the potential of synergistic action with radiotherapy.

### References

1. Djordjevich, L. and Miller, I.F. Synthetic erythrocytes from lipid encapsulated hemoglobin, *Exp. Hematol.* **8**, 584-592 (1980).
2. Tsuchida, E., Sakai, H., Horinouchi, H. and Kobayashi, K. Hemoglobin-vesicles as a transfusion alternative, *Artif. Cells Blood Substit. Biotechnol.* **34**, 581-588 (2006).
3. Kobayashi, K., Tsuchida, E. and Horinouchi, H., Ed. Artificial oxygen carrier: Its front line, *Keio University International Symposia for Life Sciences and Medicine*. Vol. 12, Springer- Verlag (2005).
4. Djordjevich, L., Mayoral, J. and Miller, I.F., *et al.* Cardiorespiratory effects of exchanging transfusions with synthetic erythrocytes in rats. *Crit. Care Med.* **15**, 318 (1987).
5. Awasthi, V. D., Garcia, D. and Klipper, R., *et al.* Neutral and anionic liposome-encapsulated hemoglobin: Effect of postinserted poly-(ethylene glycol distearoylphosphatidylethanolamine on distribution and circulation kinetics. *J. Pharmacol. Exp. Ther.* **309**, 241 (2004).
6. D'Agnillo, F. and Alayash, A.I. Redox cycling of diaspirin cross-linked hemoglobin induces G2/M arrest and apoptosis in cultured endothelial cells. *Blood*, **98**, 3315-3323 (2001).



7. **Sakai, H., Hara, H. and Yuasa, M., et al.** Molecular dimensions of Hb-based O<sub>2</sub> carriers determine constriction of resistance arteries and hypertension. *Am. J. Physiol. Heart Circ. Physiol.* **279**, H908 (2000).
8. **Sakai, H., Horinouchi, H. and Yamamoto, M., et al.** Acute 40 percent exchange-transfusion with hemoglobin-vesicles (HbV) suspended in recombinant human serum albumin solution: Degradation of HbV and erythropoiesis in a rat spleen for 2 weeks. *Transfusion*, **46**, 339 (2006).
9. **Sakai, H., Horinouchi, H. and Tomiyama, K., et al.** Hemoglobinesicles as oxygen carriers: Influence on phagocytic activity and histopathological changes in reticuloendothelial system. *Am. J. Pathol.* **159**, 1079 (2001).
10. **Sakai, H., Masada, Y. and Horinouchi, H., et al.** Physiological capacity of the reticuloendothelial system for the degradation of hemoglobin vesicles (artificial oxygen carriers) after massive intravenous doses by daily repeated infusions for 14 days. *J. Pharmacol. Exp. Ther.* **311**, 874 (2004).
11. **Vaupel, P., Mayer, A. and Hockel, M.** Tumor hypoxia and malignant progression. *Methods Enzymol.* **381**, 335-54 (2004).
12. **Vaupel, P. and Mayer, A.** Hypoxia in cancer: significance and impact on clinical outcome. *Cancer Metastasis Rev.* **26**, 225-39 (2007).
13. **Overgaard, J. and Horsman, M.R.** Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. *Semin Radiat Oncol.* **6**, 10-21(1996).
14. **Murayama, C., Suzuki, A. and Sato, C., et al.** Radiosensitization by a new potent nucleoside analog: 1-(1', 3', 4'-trihydroxy-2'- butoxy) methyl-2-nitroimidazole (PR-350). *Int. J. Radiat Oncol. Biol. Phys.* **26**, 433-43(1993).
15. **Teicher, B.A. and Rose, C.M.** Oxygen-carrying perfluorochemical emulsion as an adjuvant to radiation therapy in mice. *Cancer Res.* **44**, 4285-8 (1984).
16. **Song, C.W., Lee, I. and Hasegawa, T., et al.** Increase in PO<sub>2</sub> and radiosensitivity of tumors by Fluosol-DA (20%) and carbogen. *Cancer Res.* **47**, 442-6 (1987).
17. **Teicher, B.A., Ara, G. and Chen, Y.N., et al.** PEG-hemoglobin: Effects on tumor oxygenation and radiosensitization. *Radiat. Oncol. Invest.* **4**, 200-10 (1996).
18. **Masunaga, S., Nagasawa, H. and Uto, Y., et al.** The usefulness of continuous administration of hypoxic cytotoxin combined with mild temperature hyperthermia, with reference to effects on quiescent tumour cell populations. *Int. J. Hyperthermia*, **21**, 305-18 (2005).

19. **Overgaard, J.** Hypoxic radiosensitization: Adored and ignored. *J. Clin. Oncol.* **25**, 4066-4074 (2007).
  20. **Shen, C., Jiang, Y.M. and Shi, H., et al.** A prospective, sequential and longitudinal study of haematological profile during normal pregnancy in Chinese women. *J. Obstet. Gynaecol.* **30**(4), 357-361 (2010).
  21. **Kl ebanoff , M.A., Shiono, P.H., Selby, J.V., Tracht enberg, A.I. and Graubard, B.I.**, Anemia and spontaneous preterm birth. *Am. J. Obstet. Gynecol.* **164** (1 Pt 1), 59-63 (1991).
  22. **Allen, L.H.** Anemia and iron deficiency: Effects on pregnancy outcome. *Am. J. Clin. Nutr.* **7** (Suppl 5), 1280S-1284S (2000).
  23. **Chang, R. and Wong, G.Y.** Prognostic significance of marked leukocytosis in hospitalized patients. *J. Gen. Intern. Med.* **6**, 199-203 (1991).
  24. **Knaus, W.A., Wagner, D.P. and Draper, E.A., et al.** The APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults. *Chest*; **100**, 1619-36 (1991).
  25. **Knaus, W.A., Draper, E.A., Wagner, D.P. and Zimmerman, J.E.** APACHE II: A severity of disease classification system. *Crit. Care Med.* **13**, 818-29 (1985).
  26. **Fine, M.J., Auble, T.E. and Yealy, D.M., et al.** A prediction rule to identify low-risk patients with community-acquired pneumonia. *N. Engl. J. Med.* **336**, 243-50 (1997).
  27. **Grimm, R.H.J.R., Neaton, J.D. and Ludwig, W.** Prognostic importance of the white blood cell count for coronary, cancer, and all-cause mortality. *JAMA*; **254**, 1932-37 (1985).
  28. **De Labry, L.O., Campion, E.W., Glynn, R.J. and Vokonas, P.S.** White blood cell count as a predictor of mortality: Results over 18 years from the Normative Aging Study. *J. Clin. Epidemiol.* **43**, 153-7 (1990).
  29. **Frumin, A.M., Mendell, T.H., Mintz, S.S., Novack, P. and Faulk A.T.** Nucleated red blood cells in congestive heart failure. *Circulation*, **20**, 367-70 (1959).
  30. **Mozaffarian, D., Nye, R. and Levy, W.C.** Anemia predicts mortality in severe heart failure: The prospective randomized amlodipine survival evaluation (PRAISE). *J. Am. Coll. Cardiol.* **41**, 1933-9 (2003).
  31. **Sun, Y.** Free radicals, antioxidant enzymes and carcinogenesis. *Free Radic. Biol. Med.* **8**, 583-99 (1990).
  32. **Cerutti, P.A.** Pro-oxidant status and tumor promotion. *Science*, **227**, 375-81 (1985).
- Egypt. J. Biophys. Biomed. Engng.* **Vol. 16** (2015)

33. **Fenninger, L.D. and Mider, G.B.** Energy and nitrogen metabolism in cancer. *Adv. Cancer. Res.* **2**, 229-53 (1954).
34. **Meister, A.** Glutathione metabolism and its selective modification. *J. Biochem.* **263**, 17205-8 (1988).
35. **Klein, G. and Revesz, L.** Quantitative studies on the multiplication of neoplastic cells *in vivo*. I. growth curves of the Ehrlich and MC1M ascites tumors, *J. Natl. Cancer Inst.* **14**, 229 (1953).
36. **Elbially, Nihal, Abdelhamid, M. and Youssef, T.** Low power argon laser induced thermal therapy for subcutaneous ehrlich carcinoma in mice using spherical gold nanoparticles, *J. Biomed. Nanotechnol.* **6**, 1-7 (2010).
37. **Kabel, A. M.** Effect of combination between methotrexate and histone deacetylase inhibitors on transplantable tumor model, *American Journal of Medicine Studies*, **2** (1), 12-18 (2014).
38. **National Research Council**, "*Guide for the Care and Use of Laboratory Animals*", National Academy Press, Washington, DC (1996).
39. **Murayama, C., Kawaguchi, A.T. and Ishikawa, K., et al.**, Liposome-encapsulated hemoglobin ameliorates tumor hypoxia and enhances radiation therapy to suppress tumor growth in mice, *Artif. Organs*, **36**, 170–177 (2012).
40. **Yoshioka, T., Kawada, K., Shimada, T. and Mori, M.** Lipid peroxidation in maternal and cord blood and protective mechanism against activated oxygen toxicity in the blood, *Am. J. Obstet. Gynecol.* **135**, 372-376 (1979).
41. **Park, E., Ahn, G.N., Lee, N.H., Kim, J.M., Yun, J.S. and Hyun, J.W., et al.** Radioprotective properties of eckol against ionizing radiation in mice. *FEBS Lett.* **582**, 925-30 (2008).
42. **Benkovic, V., Knezevic, A.H., Dikic, D., Lisicic, D., Orsolcic, N. and Basic, I., et al.** Radioprotective effects of propolis and quercetin in gamma-irradiated mice evaluated by the alkaline comet assay. *Phytomedicine*; **15**, 851-8 (2008).
43. **Samarth, R.M. and Kumar, A.** Radioprotection of swiss albino mice by plant extract *Mentha pipertia (Linn)*. *J. Radiat Res.* **44**, 101-9 (2003).
44. **Fecchio, D., Sirois, P., Russo, M. and Jancar, S.** Studies on inflammatory response induced by Ehrlich tumor in mice peritoneal cavity. *Inflammation*, **14**, 125–32 (1990).
45. **Adaramoye, O. A., Adedara, I. A., Popoola, B. and Farombi, E. O.** Extract of *Xylopiya aethiopica* (Annonaceae) protects against gamma-radiation induced testicular damage in Wistar rats. *J. of Basic and Clinical Physiology and Pharmacology*, **21**, 295-313 (2010).
46. **Valavanidis, A., Vlachogianni, T. and Fiotakis, K.** Tobacco smoke: Involvement of reactive oxygen species and stable free radicals in mechanisms of oxidative damage, carcinogenesis and synergistic effects with other respirable particles. *International J. of Environmental Research and Public Health*, **6**, 445-462 (2009).

47. **Bhatia, A. L., Jain, M. and Spinacia oleracea L.** protects against gamma radiations: A study on glutathione and lipid peroxidation in mouse liver. *Phytomedicine*, **11**, 607-615 (2004).
48. **Noaman, E.L., Badr El-Din, N.K., Bibars, M.A., Abou Mossallam, A.A. and Ghoneum, M.** Antioxidant potential by arabinoxylan rice bran, MGN-3/biobran, represents a mechanism for its oncostatic effect against murine solid Ehrlich carcinoma. *Cancer Lett.* **268** (2), 348-359 (2008).
49. **Babior, B.M.** Phagocytes and oxidative stress. *Am J. Med.* **109**, 33-44 (2000).
50. **Augustine, B.B., Dash, S., Lahkar, M., Sarma, U., Samudrala, P.K. and Thomas, J.M.** Leucas aspera inhibits the Dalton's ascitic lymphoma in Swiss albino mice: A preliminary study exploring possible mechanism of action. *Pharmacogn Mag.* **10** (38),118-24 (2014).
51. **Navarro, J., Obrador, E., Pellicer, J.A., Asensi, M., Vina, J. and Estrela, J.M.** Blood glutathione as an index of radiation-induced oxidative stress in mice and humans. *Free Radic. Biol. Med.* **22**, 1203-9 (1997).

(Received 21/12/2014;  
accepted 16 / 3/2015)

## المؤشرات الدموية للفئران الحاملة لورم الأيرلش عندما تم علاجها باستخدام الليبوسومات المغلفة للهيموجلوبين وبالتشعيع

محمد اسماعيل الجوهري , سعيد عبد الفتاح على\* , نشأت أحمد دياب\*\* , محمود محمد اسماعيل و محمد حسنين جابر\*

قسم الفيزياء - كلية العلوم بنين - جامعة الازهر بالقاهرة , \* قسم الفيزياء الحيويه - كلية العلوم - جامعة القاهرة و \*\* قسم الفيزياء الطبيه - المعهد القومى للأورام - جامعة القاهرة - القاهرة - مصر .

كثيرا ما تقشل الأوعية الدموية للأورام فى توفير مستويات كافية من الأكسجين إلى الأنسجة السرطانية مما يؤدي إلى أورام بها نقص من الأكسجين ومقاومه للعلاج الإشعاعى. ولتحقيق أفضل النتائج للعلاج الإشعاعى ممكن الجمع بينه وبين الليبوسومات المغلفة للهيموجلوبين من البقر باعتبارها ناقلات صناعيه للأكسجين. ومن المعروف أن المؤشرات الدموية وتأكسد الدهون هي عوامل هامه فى التنبؤ بالأورام وعلاجها. ولذلك كان الهدف من هذا البحث هو التحقيق من تحسن النتائج العلاجيه عند الجمع بين العلاج الإشعاعى والليبوسومات المغلفة للهيموجلوبين من البقر وذلك من خلال مقارنة نتائج المؤشرات الدموية وكذلك تأكسد الدهون فى المجموعات العلاجيه المختلفه. وتم تقسيم المجموعات العلاجيه عشوائيا لخمس مجموعات من ذكور الفئران البيضاء السويسرى ثم تم تجميع عينات الدم من المجموعات العلاجيه المختلفه فى انابيب تحتوى على الهيبارين ثم تم قياس المؤشرات الدمويه وتركيز المالدندالدهايد (MDA) الناتج من تأكسد الدهون فى كل عينه ثم تم تحليل النتائج. وعند فحص نتائج خلايا الدم الحمراء أظهرت مجموعة الليبوسومات المغلفة للهيموجلوبين من البقر مع العلاج الإشعاعى نتائج جيدة فى معظم القياسات مقارنة بمجموعة العلاج الإشعاعى ومجموعة الكنترول و أظهرت ايضا مجموعة الكنترول قيم صغيرة فى مخطط خلايا الدم الحمراء مقارنة بمجموعة الفئران الطبيعیه, بينما مجموعة الليبوسومات المغلفة للهيموجلوبين من البقر مع العلاج الإشعاعى أظهرت أعلى قيم بين كل المجموعات فى مخطط خلايا الدم الحمراء.

وعلى ذلك فان هذه الدراسه قد أوضحت التأثير العلاجى المناسب فى الجمع بين الليبوسومات المغلفة للهيموجلوبين من البقر مع العلاج الإشعاعى و هذا التأثير ناتج من زيادة مستوى الأكسجين فى الخلايا السرطانيه.